Have a feature idea you'd love to see implemented?
Let us know!
INO Inovio Pharmaceuticals Inc
Price (delayed)
$1.84
Market cap
$48.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.44
Enterprise value
$38.78M
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO
Highlights
Inovio Pharmaceuticals's debt has shrunk by 58% YoY and by 4.1% QoQ
INO's EPS is up by 41% year-on-year and by 12% since the previous quarter
INO's revenue has dropped by 76% year-on-year and by 66% since the previous quarter
The gross profit has dropped by 76% year-on-year and by 66% since the previous quarter
Key stats
What are the main financial stats of INO
Market
Valuations
Earnings
Shares outstanding
26.1M
Market cap
$48.02M
Enterprise value
$38.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
254.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
190.66
Revenue
$203,413
Gross profit
$203,413
Net income
-$112.88M
EBIT
-$112.42M
EBITDA
-$109.89M
Free cash flow
-$111.03M
Per share
Balance sheet
Liquidity
EPS
-$4.44
EPS diluted
-$4.44
Free cash flow per share
-$3.95
Book value per share
$2.83
Revenue per share
$0.01
TBVPS
$3.8
Total assets
$107.06M
Total liabilities
$33.52M
Debt
$12.45M
Equity
$73.54M
Working capital
$67.79M
Debt to equity
0.17
Current ratio
3.88
Quick ratio
3.69
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
-54,021.4%
Gross margin
100%
Net margin
-55,491.1%
Operating margin
-58,709.7%
Return on assets
-83.5%
Return on equity
-118.2%
Return on invested capital
-111.3%
Return on capital employed
-134.5%
Return on sales
-55,264.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INO stock price
How has the Inovio Pharmaceuticals stock price performed over time
Intraday
-0.27%
1 week
-20.69%
1 month
-53.65%
1 year
-60.26%
YTD
-69.93%
QTD
-68.17%
Financial performance
How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$203,413
Gross profit
$203,413
Operating income
-$119.42M
Net income
-$112.88M
Gross margin
100%
Net margin
-55,491.1%
The company's operating margin has shrunk by 191% YoY and by 172% QoQ
Inovio Pharmaceuticals's net margin has shrunk by 188% YoY and by 170% QoQ
INO's revenue has dropped by 76% year-on-year and by 66% since the previous quarter
The gross profit has dropped by 76% year-on-year and by 66% since the previous quarter
Growth
What is Inovio Pharmaceuticals's growth rate over time
Valuation
What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.65
P/S
254.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
190.66
INO's EPS is up by 41% year-on-year and by 12% since the previous quarter
The stock's price to book (P/B) is 92% less than its 5-year quarterly average of 8.3 and 70% less than its last 4 quarters average of 2.2
The equity has contracted by 47% YoY and by 24% from the previous quarter
INO's revenue has dropped by 76% year-on-year and by 66% since the previous quarter
The P/S is 43% lower than the last 4 quarters average of 446.2 and 29% lower than the 5-year quarterly average of 358.5
Efficiency
How efficient is Inovio Pharmaceuticals business performance
INO's return on sales has dropped by 189% year-on-year and by 171% since the previous quarter
INO's return on assets is down by 32% year-on-year and by 8% since the previous quarter
INO's ROE is down by 31% YoY and by 9% from the previous quarter
The company's return on invested capital fell by 25% YoY and by 13% QoQ
Dividends
What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INO.
Financial health
How did Inovio Pharmaceuticals financials performed over time
The total assets has declined by 45% year-on-year and by 20% since the previous quarter
The company's total liabilities fell by 39% YoY and by 10% QoQ
Inovio Pharmaceuticals's debt is 83% lower than its equity
Inovio Pharmaceuticals's debt has shrunk by 58% YoY and by 4.1% QoQ
The equity has contracted by 47% YoY and by 24% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.